Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing locally delivered drug-device therapies for ear, nose and throat (ENT) disorders. Founded in 2014 and headquartered in Massachusetts, Lyra leverages its proprietary NOV-embedded matrix platform to provide sustained release of therapeutic agents directly to targeted sinonasal and middle ear tissues. The company’s mission is to address chronic ENT conditions with innovative, minimally invasive treatments that improve patient outcomes and reduce systemic side effects associated with traditional therapies.

The company’s lead product candidate, LYR-210, is a biodegradable implant designed to deliver mometasone furoate over a six-month period directly to the sinonasal mucosa in patients with chronic rhinosinusitis (CRS). LYR-210 is currently in Phase 2 clinical development, with data expected to support advancement toward late-stage trials. Lyra’s pipeline also includes LYR-220, a higher-dose implant for CRS, and early-stage programs exploring therapies for otitis media with effusion and noise-induced hearing loss, all leveraging the same sustained-release technology.

Lyra Therapeutics completed its initial public offering in early 2021 and has grown its leadership team with industry veterans in clinical development, regulatory affairs and operations. Mark A. Sirgo serves as President and Chief Executive Officer, bringing more than two decades of biopharmaceutical experience, while a board of directors with deep expertise in drug development and medical devices guides the company’s strategic direction. The company maintains strong ties to academic research institutions and has attracted funding from leading life sciences investors.

Primarily focused on the United States market, Lyra is also exploring partnerships and regulatory pathways to expand into Europe and other regions. By concentrating on chronic and underserved ENT indications, the company aims to transform standard of care through localized, long-acting therapeutics that meet significant patient needs and reduce the burden of repeat interventions.

Key Stats

• Today's Range: $8.55 to $8.98
• 50-Day Range: $4.39 to $27.58
• 52-Week Range: $3.81 to $37.50
• Volume: 42,864 shs
• Average Volume: 193,704 shs
• Market Capitalization: $11.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.00
• Consensus Rating: Hold

Lyra Therapeutics Stock Analysis - MarketRank™

Lyra Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 598th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lyra Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyra Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyra Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lyra Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.74% of the float of Lyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently increased by 8.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyra Therapeutics does not currently pay a dividend.

Dividend Growth

Lyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.74% of the float of Lyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently increased by 8.88%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.94

News Sentiment

Lyra Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Lyra Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 6 people have searched for LYRA on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.25% of the stock of Lyra Therapeutics is held by insiders.

Percentage Held by Institutions

95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYRA Stock Analysis - Frequently Asked Questions

How have LYRA shares performed this year?

Lyra Therapeutics' stock was trading at $10.32 on January 1st, 2025. Since then, LYRA shares have decreased by 16.2% and is now trading at $8.65.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($6.00) EPS for the quarter, beating the consensus estimate of ($7.50) by $1.50. The business had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.16 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 295.52% and a negative net margin of 6,711.39%.

When did Lyra Therapeutics' stock split?

Shares of Lyra Therapeutics reverse split before market open on Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an initial public offering (IPO) on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LYRA
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lyra Therapeutics: $100.00
• High Price Target: $100.00
• Low Price Target: $100.00
• Potential Upside/Downside: +1,056.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($60.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$93.43 million
• Net Margins: -6,711.39%
• Pretax Margin: -6,708.94%
• Return on Equity: -295.52%
• Return on Assets: -66.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.96
• Quick Ratio: 2.96

Sales & Book Value

• Annual Sales: $1.53 million
• Price / Sales: 7.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.86 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 1,330,000
• Free Float: 1,282,000
• Market Cap: $11.50 million
• Optionable: Optionable
• Beta: 0.24